Critical Path Institute

As BIO 2026 approaches, Critical Path Institute is looking forward to connecting with colleagues across industry, academia, patient advocacy, investment, and regulatory science.

BIO is always a valuable opportunity to listen, learn, and explore where collaboration can help address persistent challenges in drug development.

This year, we’re especially interested in conversations around:
➡️ Strategic partnerships that support shared priorities across the biomedical ecosystem
➡️ Translational therapeutic programs and what they need to move toward IND readiness
➡️ Emerging pathways for advanced therapies, including gene, cell, siRNA, A*O, and individualized medicines
➡️ Collaboration with patient advocacy groups and disease foundations to ensure patient needs remain central
➡️ Regulatory science, evidence generation, and collaborative infrastructure that can help reduce development uncertainty

We’re looking forward to thoughtful conversations in San Diego about how partners across the ecosystem can work together to accelerate therapies for patients with unmet medical needs.

If you’ll be attending BIO 2026, we’d welcome the opportunity to connect through the BIO Partnering App.

Interested in C-Path updates? Be sure to subscribe at https://f.mtr.cool/yzxgpnafqa For 20 years, C-Path has been providing vital infrastructure to generate a neutral environment for everyone working in drug development to collaborate, not compete. Let's improve lives, together.